Glucagon Receptor

GCGR

Glucagon receptor is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Glucagon Receptor Inhibitors, Agonists, Antagonists & Modulators

Adomeglivant
(LY2409021)

Cat. No.: HY-19904

Adomeglivant is a potent and selective glucagon receptor antagonist that is used in clinical trial for type 2 diabetes mellitus.



Purity: 99.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Albiglutide TFA

Cat. No.: HY-108795A

Albiglutide TFA, a glucagon-like peptide (GLP)-1 mimetic, is a long acting **GLP-1 receptor** agonist for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide TFA is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Avexitide
(Exendin (9-39))

Cat. No.: HY-P0264

Avexitide (Exendin (9-39)) is a specific and competitive **GLP-1** receptor antagonist.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

BETP

Cat. No.: HY-103546

BETP is an agonist of **glucagon-like peptide-1 (GLP-1) receptor**, with EC_{50}s of 0.66 and 0.755 µM for human and rat **GLP-1 receptor**, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cotadutide acetate
(MEDI0382 acetate)

Cat. No.: HY-P2231A

Cotadutide acetate (MEDI0382 acetate) is a potent peptide dual agonist of **glucagon-like peptide-1 (GLP-1)** and glucagon receptor with EC_{50} values of 6.9 pM and 10.2 pM, respectively.



Purity: 96.67%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

Exendin-3/4 (59-86)

Cat. No.: HY-P1223

Exendin-3/4 (59-86) is a Exendin-4 peptide derivative.

Purity: 97.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Exendin-4
(Exenatide)

Cat. No.: HY-13443

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting **glucagon-like** peptide-1 receptor agonist with an IC_{50} of 3.22 nM.

Purity: 99.44%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

Exendin-4 Acetate
(Exenatide acetate)

Cat. No.: HY-13443A

Exendin-4 Acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting **glucagon-like** peptide-1 receptor agonist with an IC_{50} of 3.22 nM.

Purity: 99.44%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Cat. No.: HY-P1229

FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GIP (1-30) amide,Human

Cat. No.: HY-P2080

GIP (1-30) amide,Human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

GIP (1-30) amide,Human acetate

Cat. No.: HY-P2080B

GIP (1-30) amide,Human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GLP-1 moiety from Dulaglutide

Cat. No.: HY-P1348

GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

Purity: 96.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 1

Cat. No.: HY-112185

GLP-1 receptor agonist 1 is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GLP-1 receptor agonist 2

Cat. No.: HY-112679

GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor **(GLP-1R)** agonist.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GLP-1 receptor agonist 3

Cat. No.: HY-129656

GLP-1 receptor agonist 3 is a **GLP-1 receptor** agonist extracted from patent WO2018109607A1, Example 4A-1, has **EC_{50}**s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 4

Cat. No.: HY-129657

GLP-1 receptor agonist 4 is a **glucagon-like peptide-1 receptor (GLP-1R)** agonist extracted from patent WO2009111700A2, compound 87, has an **EC_{50}** of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1(7-36) Acetate

(Human GLP-1-(7-36)-amide Acetate)

Cat. No.: HY-P0054

GLP-1(7-36) Acetate (Human GLP-1-(7-36)-amide Acetate) is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

GLP-1(7-37)

Cat. No.: HY-P0055

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

GLP-1(7-37) acetate

Cat. No.: HY-P0055A

GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

GLP-1R Antagonist 1

Cat. No.: HY-101116

GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of **glucagon-like peptide 1 receptor (GLP-1R)**, with an **IC_{50}** of 650 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-2(1-33)(human)

(GLP-2 (human); Glucagon-like peptide 2 (human))

Cat. No.: HY-P1024

GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the **GLP-2 receptor** and stimulate the growth of intestinal epithelium.

HADGSFSDEMNTILDNLAARDFINWLIQTKITD

Purity: 95.12%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Glucagon

(Porcine glucagon)

Cat. No.: HY-P0082

Glucagon (Porcine glucagon) is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis. Glucagon decreases the activity of **HNF-4**. Glucagon increases HNF4α phosphorylation.

HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

Purity: 96.85%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Glucagon hydrochloride

(Porcine glucagon hydrochloride)

Cat. No.: HY-P0082A

Glucagon hydrochloride (Porcine glucagon hydrochloride) is a peptide hormone, produced by pancreatic α-cells. Glucagon hydrochloride stimulates gluconeogenesis. Glucagon hydrochloride decreases the activity of **HNF-4**. Glucagon hydrochloride increases HNF4α phosphorylation.

HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
H-Cl

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucagon receptor antagonists-1

Cat. No.: HY-10036

Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Glucagon receptor antagonists-2

Cat. No.: HY-50158

Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.



Purity: 97.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glucagon receptor antagonists-3

Cat. No.: HY-50159

Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glucagon receptor antagonists-5

Cat. No.: HY-128781

Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based **glucagon receptor** antagonist (K_i=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucagon-Like Peptide (GLP) I (7-36), amide, human

(Human GLP-1-(7-36)-amide)

Cat. No.: HY-P0054A

Glucagon-Like Peptide (GLP) I (7-36), amide, human (Human GLP-1-(7-36)-amide) is a physiological incretin hormone that stimulates insulin secretion.

HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucagon-like peptide 1 (1-37), human

(HuGLP-1)

Cat. No.: HY-P1145

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the **GLP-1 receptor**.

HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucagon-like peptide 1 (1-37), human TFA

(HuGLP-1 TFA)

Cat. No.: HY-P1145A

Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the **GLP-1 receptor**.

HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (TFA salt)

Purity: 97.18%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

GRA Ex-25

Cat. No.: HY-50675

GRA Ex-25 is an inhibitor of **glucagon receptor**, with IC_{50} of 56 and 55 nM for rat and human glucagon receptors, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Cat. No.: HY-P1231

GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.

Purity: 99.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFT

Cat. No.: HY-P1228

HAEGTFT is the first N-terminal 1-7 residues of GLP-1 peptide.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFTSD

Cat. No.: HY-P1226

HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFTSDVS

Cat. No.: HY-P1224

HAEGTFTSDVS is the first N-terminal 1-11 residues of GLP-1 peptide.

HAEGTFTSDVS

Purity: 98.31%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Human growth hormone-releasing factor

(Growth Hormone Releasing Factor human)

Cat. No.: HY-P0089

Human growth hormone-releasing factor stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary.

Human growth hormone-releasing factor

Purity: 98.28%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

LGD-6972

Cat. No.: HY-12525

LGD-6972 is a **glucagon** receptor antagonist.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Liraglutide

Cat. No.: HY-P0014

Liraglutide is a **glucagon-like peptide-1** (**GLP-1**) receptor agonist used clinically to treat type 2 diabetes mellitus.



Purity: 99.71%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Lixisenatide

Cat. No.: HY-P0119

Lixisenatide is a **glucagon-like peptide-1 (GLP-1) receptor** agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

Purity: 98.36%
Clinical Data: Launched
Size: 1 mg, 2 mg, 5 mg, 10 mg

Lixisenatide acetate

Cat. No.: HY-P0119A

Lixisenatide acetate is a **glucagon-like peptide-1 (GLP-1) receptor** agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

MK 0893

Cat. No.: HY-50663

MK 0893 is a potent and selective **glucagon receptor** antagonist with an IC_{50} of 6.6 nM.



Purity: 99.22%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NNC-0640

Cat. No.: HY-124622

NNC-0640 is a potent **human G-protein-coupled glucagon receptor (GCGR)** negative allosteric modulator (NAM) with an IC_{50} of 69.2 nM.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PF-06291874

(Glucagon receptor antagonists-4)

Cat. No.: HY-19947

PF-06291874 (Glucagon receptor antagonists-4) is a highly potent and orally active **glucagon receptor** antagonist. It displays low in vivo clearance in both rats and dogs.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PF-06882961

Cat. No.: HY-125824

PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (**GLP-1R**).



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Secretin (33-59), rat

(Secretin (rat))

Cat. No.: HY-P1244

Secretin (33-59), rat is a 27-aa peptide, acts on **secretin receptor**, enhances the secretion of bicarbonate, enzymes, and K^+ from the pancreas.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Secretin (33-59), rat TFA

(Secretin (rat) (TFA))

Cat. No.: HY-P1244A

Secretin (33-59), rat (TFA) is a 27-aa peptide, which acts on **secretin receptor**, and enhances the secretion of bicarbonate, enzymes, and K^+ from the pancreas.

Purity: 96.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Semaglutide

Cat. No.: HY-114118

Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 **(GLP-1)** receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.



Purity: >99.0%
Clinical Data: Launched
Size: 500 μg, 1 mg, 5 mg

Semaglutide TFA

Cat. No.: HY-114118A

Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 **(GLP-1)** receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.



Purity: 98.24%
Clinical Data: Launched
Size: 500 μg, 1 mg, 5 mg

Shanzhiside methyl ester

Cat. No.: HY-N0630

Shanzhiside methy lester is isolated from L. rotata. Shanzhiside methyl ester is a small molecule **glucagon-like peptide-1 (GLP-1) receptor** agonist and has the ability to induce anti-allodynic tolerance.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Taspoglutide

(ITM077; R1583; BIM51077)

Cat. No.: HY-P0165

Taspoglutide is a long-acting glucagon-like peptide 1 (**GLP-1**) receptor agonist developed for treatment of type 2 diabetes, with an EC_{50} value of 0.06 nM. Sequence: His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-{Aib}-Arg-NH2.

Purity: 97.17%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Tirzepatide

(LY3298176) Cat. No.: HY-P1731

Tirzepatide (LY3298176) is a dual **glucose-dependent insulinotropic polypeptide (GIP)** and **glucagon-like peptide-1 (GLP-1) receptor** agonist that is being developed for the treatment of type 2 diabetes.

Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Tirzepatide hydrochloride

(LY3298176 hydrochloride) Cat. No.: HY-P1731B

Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual **glucose-dependent insulinotropic polypeptide (GIP)** and **glucagon-like peptide-1 (GLP-1) receptor** agonist that is being developed for the treatment of type 2 diabetes.

Purity: 98.85%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tirzepatide TFA

(LY3298176 TFA) Cat. No.: HY-P1731A

Tirzepatide TFA (LY3298176 TFA) is a dual **glucose-dependent insulinotropic polypeptide (GIP)** and **glucagon-like peptide-1 (GLP-1) receptor** agonist that is being developed for the treatment of type 2 diabetes.

Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

TT-OAD2

Cat. No.: HY-129658A

TT-OAD2 is a non-peptide **glucagon-like peptide-1 (GLP-1) receptor** agonist with an EC_{50} of 5 nM. TT-OAD2 has the potential for diabetes treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TT-OAD2 free base

Cat. No.: HY-129658

TT-OAD2 free base is a non-peptide **glucagon-like peptide-1 (GLP-1) receptor** agonist with an EC_{50} of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU0453379

Cat. No.: HY-116819

VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of **glucagon-like peptide-1R (GLP-1R)** with an EC_{50} of 1.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

{Val1}-Exendin-3/4

Cat. No.: HY-P1225

{Val1}-Exendin-3/4 is the first N-terminal 1-28 residues of Exendin-4 peptide.

VSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Purity: 99.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg